Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma

INTRODUCTION: Bevacizumab has demonstrated activity in glioblastoma (GBM), but the true benefits and optimal dose‐schedule are debated. A lower dose‐schedule than standard‐dose bevacizumab (10 mg/kg 2‐weekly) might offer similar benefits with lower costs. At our Institution, patients are randomly as...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Gleeson, Jack Patrick, Keane, Fergus, Keegan, Niamh M., Mammadov, Emin, Harrold, Emily, Alhusaini, Abdullah, Harte, Jeffrey, Eakin‐Love, Austin, O'Halloran, Philip J., MacNally, Stephen, Hennessy, Bryan T., Breathnach, Oscar S., Grogan, Liam, Morris, Patrick G.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6970030/
https://ncbi.nlm.nih.gov/pubmed/31756059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2616
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados